It is not too late to solve the know-how problem in the WHO Pandemic...
Introduction
One of the most important Intellectual Property (IP) problems which the Pandemic Accord negotiators need to solve is now in danger of being completely...
The world needs a signal that multilateralism works: ML&P opening statement to the INB13,...
Thank you for the opportunity to make a brief statement.
The negotiations for the Pandemic Agreement enter the final phase. We hope and wish for...
The Power of TRIPS Flexibilities in Medicines Procurement
The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV). Treatment will be a combination of...
Fair Medicines Pricing requires addressing monopolies and increasing transparency in pharmaceutical markets
The 4th WHO Fair Pricing Forum took place from 6 - 8 February 2024. Ellen 't Hoen spoke at the opening plenary. Below are...
Wrapping Up 2017 – some noteworthy medicines law and policy events.
2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12...
Updated TRIPS Flexibilities Database
In January 2023, a number of cystic-fibrosis patient organisations asked the governments of Brazil, India, South Africa and Ukraine to invoke compulsory licensing and...
Covid-19 and the comeback of compulsory licensing
The Covid-19 outbreak raises many questions, including some we can answer using experiences gained in previous disease outbreaks. Here is one: how to deal...
A better way to solve a crisis: A new mechanism for incentivising R&D on...
Antimicrobial resistance is the ‘silent’ pandemic: Globally, it costs 5 million lives a year, and is set to rise to more than 8 million...
Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...
This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....
Cystic Fibrosis Medicines Wars in Europe
Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...